Introduction {#sec1-1}
============

Chronic bronchitis is a well-defined clinical condition in contemporary medical science classified under the broader heading of chronic obstructive pulmonary diseases (COPD) that is a progressive preventable condition, without cure. In modern medicine; antibiotics, anti-histaminics, bronchodilators, expectorants etc., are commonly used for the management of chronic bronchitis. Although, they are effective in reducing the severity of the disease and suppressing the symptoms; none of these modalities of treatment provide a permanent cure and have limitations owing to their unwanted effects.

Chronic obstructive pulmonary diseases hitherto under-diagnosed in India is now recognized in 4--10% of adult male population of India and other Asian countries.\[[@ref1]\] Chronic bronchitis is more common in middle-aged males than in females. Approximately 20% of adult males and 5% of adult women are affected.\[[@ref1]\] Global initiative for chronic obstructive lung disease estimates suggests that COPD will rise from the sixth to the third most common cause of death worldwide by 2020.\[[@ref2]\]

*Vyaghriharitaki Avaleha* (VHA),\[[@ref3]\] a classical Ayurvedic formulation has been in use for ages and has been found to be useful in treating respiratory disorders and promoting health. The present study has been undertaken to generate scientific data and validate the effect of this Ayurvedic formulation in chronic bronchitis.

Materials and Methods {#sec1-2}
=====================

Clinically diagnosed patients of chronic bronchitis were selected from Outdoor and Indoor patient department (OPD/IPD) of IPGT and RA Hospital, Gujarat Ayurved University, Jamnagar. The formulation, VHA, supplied by Central Council for Research in Ayurvedic Sciences (CCRAS), New Delhi, manufactured at Arya Vaidya Sala Factory, Kanjikode, Palakkad, Kerala, specially prepared for the present clinical trial using the ingredients and method of preparation given in Ayurvedic Pharmacopoeia of India (API). This work has been cleared by Institutional Ethics Committee (IEC) vide Ref. PGT/7-A/Ethics/2010-2011/3381 dated 10/01/2011 and was registered with Clinical Trial Registry of India (CTRI) vide CTRI/2011/11/002142. It was an interventional, open label, prospective type of clinical trial with the purpose of treatment with the endpoints of efficacy and safety of the trial drug, VHA with proper arrangements for withdrawals. No control group was used.

Inclusion criteria {#sec2-1}
------------------

Patients of either sex aged between 16 and 70 years with a history of uncomplicated chronic bronchitis who were willing and able to participate in the study for 16 weeks.

Exclusion criteria {#sec2-2}
------------------

Patients suffering from acute bronchitis having peak expiratory flow rate (PEFR) \<50% of the predicted value and having other pulmonary diseases like emphysema, cor-pulmonale, cyanosis, pneumonia, asthma, cystic fibrosis, tuberculosis, lung cancer etcPatients with poorly controlled diabetes mellitus (HbA1c \> 10%) and poorly controlled hypertension (\>160/100 mm of Hg), patients on prolonged (\>6 weeks) medication with corticosteroids, bronchodilators, mast cell stabilizers, antidepressants, anticholinergics, etc., or other drugs that may have an influence on the outcome of the studyPatients suffering from major systemic illness necessitating long term drug treatment (rheumatoid arthritis, tuberculosis, psycho-neuro-endocrinal disorders, etc.) and patients with clinical evidence of heart failure.

Posology {#sec2-3}
--------

The test drug *Vyaghriharitaki Avaleha* was administered orally in the dose of 10 g twice a day before meals with lukewarm water for a period of 12 weeks. Patients were guided with dos and don'ts regarding diet and lifestyle. Patients were followed-up for next 4 weeks of active treatment.

Assessment parameters {#sec2-4}
---------------------

The primary outcome measure was change in the clinical symptoms of chronic bronchitis, and the secondary outcome measure was change in St. George\'s Respiratory Questionnaire (SGRQ) scores.\[[@ref4]\] The changes in the disease state of chronic bronchitis were recorded and analyzed. Improvement was assessed by adopting standard method and scoring. Functional efficiency of the respiratory system (PEFR and forced expiratory volume in 1 s \[FEV~1~\]) were assessed both before and after the intervention using Electronic Lung Health Meter (Brand name: PIKO-1; manufactured by nSpire Health, USA) and functional ability is assessed with the help of the SGRQ every 14 days of intervention and at the end of the follow-up period. Clinical assessment was done on the basis of six chief complaints related to chronic bronchitis (productive cough, dyspnea, wheezing, chest pain, sore throat and nasal congestion). Each symptom was graded as - 0 for absence of symptom and 1 for presence of symptom.

Statistical analysis {#sec2-5}
--------------------

The data generated in the clinical study was analyzed by applying Student\'s *t*-test using statistical software - SigmaStat 3.5, SYSTAT Software, USA.

### Interpretation of results {#sec3-1}

≤25% - Unchanged26--50% - Mild positive response51--75% - Moderate positive response\>75% - Marked positive response.

Observations and Results {#sec1-3}
========================

A total of 66 subjects were enrolled in this trial with the purpose of treatment, out of which 61 (92.42%) completed the treatment schedule, and 05 (7.58%) were dropped out. The details are summarized and depicted in [Flow Chart 1](#F1){ref-type="fig"}.

![Summarizing the enrollment of patients](AYU-36-50-g001){#F1}

Distribution of patients according to age, gender and allergic factors as experienced by the patients are depicted at the Tables [1](#T1){ref-type="table"}--[3](#T3){ref-type="table"} respectively. The cardinal symptom of chronic bronchitis is a productive cough that was present in 100% patients. Dyspnoea in 62.12%, wheezing in 57.58%, chest pain in 34.85%, sore throat in 56.06% and nasal congestion in 71.21% patients was observed. Maximum numbers of subjects included in the trial (54.55%) were suffering from chronic bronchitis for 2 to 5 years \[[Table 4](#T4){ref-type="table"}\]. Around 25.76% of enrolled patients had been chronic smokers with a history of \>5 years \[[Table 5](#T5){ref-type="table"}\]. About 40.91% patients had irregular bowel habits and 39.39% patients had constipation.

###### 

Distribution of 66 patients according to age

![](AYU-36-50-g002)

###### 

Distribution of 66 patients according to their gender
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###### 

Distribution of patients according to allergy
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###### 

Distribution of subjects according to chronicity
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###### 

Distribution of subjects according to duration of smoking (regular + ex-smoker)
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Results {#sec1-4}
=======

Effect of therapy on primary outcome {#sec2-6}
------------------------------------

Maximum 100% result was found in wheezing, chest pain and sore throat, 97.62% relief in nasal congestion, 83.3% in dyspnoea and 68.9% relief in productive cough was noticed after treatment. This improvement is statistically highly significant (*P* \< 0.001) \[[Table 6](#T6){ref-type="table"}\].

###### 

Effect on chief complaints

![](AYU-36-50-g007)

Effect of therapy on secondary outcome {#sec2-7}
--------------------------------------

Change in total score of SGRQ was 59.23% that was statistically highly significant (*P* \< 0.001). The improvement in the modified total score (calculated on the basis of activity and impact scores, excluding the symptoms scores) was 82.14%, which was statistically highly significant (*P* \< 0.001) \[[Table 7](#T7){ref-type="table"}\].

###### 

Effect on the SGRQ scores

![](AYU-36-50-g008)

Effect of therapy on FEV~1~ and PEFR {#sec2-8}
------------------------------------

There was a slight increase of 1.09% in mean FEV~1~ value and a slight decrease of 0.45% in the mean PEFR value. Both the changes were statistically insignificant \[[Table 8](#T8){ref-type="table"}\].

###### 

Effect on FEV~1~ and PEFR
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Overall effect of therapy on the basis of Total Score of SGRQ {#sec2-9}
-------------------------------------------------------------

On the basis of changes in the total Score of SGRQ also, the overall effect of the drug on Chronic bronchitis was assessed. It was observed that 07 (11.48%) patients got marked positive response with the treatment, whereas 34 (55.74%) patients got moderate (50-75%) positive response, whereas 15 (24.59%) patients got mild positive response. The remaining 05 (8.20%) patients did not observe any significant change in their condition \[[Table 9](#T9){ref-type="table"}\].

###### 

Overall effect of therapy on the basis of total score of SGRQ

![](AYU-36-50-g010)

The 12-month version of SGRQ was used which is the original validated version. The patient has to give the answers to the part-1 (which is related with Symptom score) by recalling his perception for the whole last year, there was no much difference expected in Symptoms score during the 12 weeks of clinical study. So, to get the appropriate picture of the effect of therapy the change in the Total Score was calculated on the basis of changes in the Activity and Impact Scores. The modified calculation shows that 45 (73.77%) patients got marked positive response with the treatment, whereas 10 (16.39%) patients got moderate positive response, whereas 02 (3.28%) patients got mild positive response. The remaining 04 (6.56%) patients did not observed any significant change in their condition \[[Table 10](#T10){ref-type="table"}\]. This is much similar to the overall effect of the therapy calculated on the basis of symptomatic relief to the patient.

###### 

Overall effect of therapy on the basis of total score of SGRQ calculated without symptom score

![](AYU-36-50-g011)

Overall effect of therapy on the basis of symptomatic relief {#sec2-10}
------------------------------------------------------------

Overall effect on symptomatic relief is placed at [Table 11](#T11){ref-type="table"}. It provided marked positive improvement in 89.52% patients whereas 9.84% patients got moderate positive response. Only one patient did not get any response to the treatment in whom the disease was prevalent for the past 20 years.

###### 

Overall effect of therapy on the basis of symptomatic relief

![](AYU-36-50-g012)

Effect on hematological and bio-chemical parameters {#sec2-11}
---------------------------------------------------

Comparative effect of therapy on hematological investigations was statistically insignificant except on differential counts of neutrophils and lymphocytes which were statistically significant. This may be an indication of positive improvement in the endogenous factors like deranged immunity. The comparative effect of therapy on bio-chemical parameters was statically insignificant except on conjugated bilirubin that was statistically significant (*P* = 0.005). This signifies the positive effect of the drug on liver function and general metabolism \[[Table 12](#T12){ref-type="table"}\].

###### 

Effect on hematological and biochemical parameters

![](AYU-36-50-g013)

All patients maintained the "status quo" during the follow-up period. No patient showed either aggression in the status or recurrence. No adverse drug reaction to the trial drug was reported during the study. No rescue medications were used during the study as it was not warranted. None of the subjects were required to be withdrawn from the study as there was no serious health condition requiring referral occurred during the study period.

Discussion {#sec1-5}
==========

On the basis of relief in the symptoms to the patients, the overall effect of the drug on chronic bronchitis was assessed. It was observed that 89.52% patients got marked positive response with the treatment, whereas 9.84% got moderate (50--75%) positive response. The remaining 1 (1.64%) patient did not get any significant change in his condition.

The mean total score in SGRQ prior to treatment was 32.369 and after the treatment was 13.196, with a difference of 59.23% that is statistically highly insignificant with *P* \< 0.001. The improvement in the modified Total score (calculated on the basis of activity and impact scores) was 82.14% that was statistically highly significant (*P* \< 0.001).

This overall effect of the therapy shows that *Vyaghriharitaki* is very effective in the management of chronic bronchitis showing better improvements in both primary and secondary outcome measures.

Probable mode of action of *Vyaghriharitaki Avaleha* {#sec2-12}
----------------------------------------------------

*Vyaghriharitaki Avaleha* a polyherbal Ayurvedic formulation having major ingredients - *Kantakari* (*Solanum xanthocarpum* Schrad. and Wendl.), *Haritaki* (*Terminalia chebula* Retz.). Studies on *S. xanthocarpum* confirm its traditional use in bronchial asthma. The clinical efficacy of two herbs *S. xanthocarpum* and *Solanum trilobatum* Linn. in a dose of 300 mg tds for 3 days was investigated in mild to moderate bronchial asthma. Their effect was compared with standard bronchodilator drugs, salbutamol (4 mg) and deriphylline (200 mg). *S. xanthocarpum* and *S. trilobatu*m produced a progressive improvement in the vantilatory function of asthmatic individuals over 3 days. The scores for ronchi, cough, breathlessness and sputum were decreased by these drug treatments. The improvement in PEFR and the reduction in other symptom scores clearly indicate a bronchodialator effect, a decrease of edema and secretions in the airway lumen. The response of these drugs can be considered to be that of deriphylline but less than salbutamol.\[[@ref5]\]

Immunostimulatory activity of aqueous extract of *S. xanthocarpum* fruits on mice gives strong evidence that the plant is an immunostimulating agent.\[[@ref6]\]

*Haritaki* (*T. chebula*) has been mentioned as the best *Rasayana* drug. *T. chebula* is having immunomodulatory activity.\[[@ref7]\] With the help of various *Samsakaras*, *Haritaki* has been mentioned to be effective in various diseases with entirely different pathophysiology. This is possible due to the *Sanskaranuvartana* and *Rasayana* property. The *Rasayana* property is due to its *Doshashamaka*, *Srotoshodhana* and *Vatanulomana* property. This is the prime condition for the *Rasayana* effect.\[[@ref8]\] With these inherited property (*Prakriti* of *Dravya*) when combined and processed with other drugs (*Samskara*), this *Haritaki* shows the result accordingly.\[[@ref9]\]

The contents of *Trikatu* (*Shunthi* \[*Zingiber officinale* Roxb.\], *Maricha* \[*Piper nigrum* Linn.\] and *Pippali* \[*Piper longum* Linn.\]) and *Chaturjat* (*Tvak* \[*Cinnamomum zeylanicum* Blume.\], *Ela* \[*Elettaria cardamomum* Maton.\], *Dalchini* \[*Cinnamomum tamala* Ness.\] and *Nagakeshara* \[*Mesua ferrea* Linn.\]) are also effective in *Kasa*. But, when these drugs are used as *Prakshepa*, the main purpose remains to be *Deepana*, *Pachana* effect and helps in improving the bioavailability of the drugs with which they are used in. *Madhu* (honey) and *Guda* (jaggery) do also possess *Kaphahara* and *Kasahara* property.\[[@ref10][@ref11]\]

In nutshell, the formulation VHA is effective in chronic bronchitis by acting on the *Samavayi Karanas* (*Doshas*) and *Asamavayi Karanas* (*Vishamashana, Vegdharana, Kshaya* etc.). Its effect on the *Asamavayi Karanas* is the additional benefit over all the treatment modalities in the modern medical science.

For the sake of simplification and easy understanding, the manifestation of the disease can be summarized as the end result of three factors - *Doshaprakopa*, *Agnidushti and Srotodushti* (*Khavaigunya*). *Agnidushti*, in itself, can take place as an effect of *Vishamashana*, *Vegadharana* and *Dhatukshaya*. There is a vicious cycle of *Agnidushti* and *Doshaprakopa* (either can be cause or effect of each other).

The *Doshaprakopa* is corrected by the *Doshashamana* property of VHA. The effect of *Vishamashana* is corrected by the *Srotoshodhana* and *Agnivardhana* property of VHA. The effect of *Vega-Vidharana* is corrected by *Anulomana* property of VHA. The *Srotodushti* is corrected with the *Srotoshodhana* and *Vishadikarana* property. With its *Brihana* property, VHA helps in correcting the *Dhatukshaya*.

*Prakrita Kapha* is essential for proper functioning of the *Pranavaha Srotasa* (and all other functions in the body that depends on *Kapha*). When the *Agni* and digestion are corrected, quality *Rasa Dhatu* is produced and this results in the production of *Prakrita Shleshama* (as *Mala* of *Rasa Dhatu*). Thus, VHA helps not only in correcting the three main factors of the disease-*Doshaprakopa*, *Agnidushti* and *Khavaigunya*, but also helps in maintaining the proper functioning of the system, which results in sustained positive effect on the *Srotasa* (*Prakriti sthapana*).

Further, *Pranavaha Srotasa* is *Vata-Kapha-Sthana*. Its function is mainly affected by vitiation of *Kapha* and *Vata*. Therefore, the *Avastha* of any respiratory disease can be as either *Vatavritta-Kapha* or *Kaphavritta-Vata* (*Prana*). If it is *Kaphavritta Avastha*, then *Doshashamana* property of VHA helps in relieving the symptoms and if it\'s *Vatavritta Avastha*, then *Vatashamana* and *Vatanulomana* property helps in relieving the symptoms. Therefore, VHA is a drug that may be effective in all the respiratory diseases as mentioned in its *Phalashruti*.

*Vyaghriharitaki Avaleha*, as a whole, corrects the effect of *Asamavayi Nidana* of the disease. Theoretically, it is a better drug for *Kasa* of *Kshayaja* type. But, at the same time, *Haritaki* with its *Srotoshodhana* and *Tridosh-Hara* property will be effective in all types of *Kasa* (chronic bronchitis). The only difference is that *Doshika* variety of *Kasa* can be better handled in relatively shorter duration with the specific treatment procedures indicated for individual *Doshika* variations. VHA can be helpful in all types of *Kasa* or Chronic bronchitis.

Conclusion {#sec1-6}
==========

*Vyaghriharitaki Avaleha* gives a significant improvement in both primary and secondary outcome measures of chronic bronchitis.
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